NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis

Madrigal Pharmaceuticals, Inc. (MDGL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MDGL

$457.96

−$9.58 (−2.05%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MDGL with… →

MDGL Key Statistics

As of Oct 21, 2026
Trading
Open
$467.90
Previous Close
$467.54
Day's Range
456.65–481.87
52-Week Range
393.61–615.00
Volume
338.29K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−1.05
Valuation
Market Cap
$10.58B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
47.58
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
8.24
EPS (ttm)Profit attributable to each share over the last twelve months.
−12.85
Financials (FY)
Revenue (FY)
$958.40M+432.05%
Net Income (FY)
−$288.28M
Profit marginThe share of revenue left as profit after all costs and taxes.
−25.32%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
23.10M
1-Year Return
+6.50%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
295.91K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MDGL closed at $457.96, +6.50% over 1 year.

Madrigal Pharmaceuticals, Inc. (MDGL) has a market capitalization of $10.58B.

In fiscal 2025, MDGL reported revenue of $958.40M.

MDGL Stock Return by Calendar Year

Madrigal Pharmaceuticals, Inc. (MDGL) 10-year return: what $10,000 became

1 year
$10,000 $10,650
+6.50%
5 years
$10,000 $59,160
+491.60%
10 years
$10,000 $269,388
+2,593.88%

If you had invested $10,000 in Madrigal Pharmaceuticals, Inc. (MDGL) 10 years ago, at the close on October 21, 2016, it would have been worth $269,388 at the close on October 21, 2026: +2,593.88% in total, +39.01% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−21.36%
2025+88.72%
2024+33.36%
2023−20.28%
2022+242.52%
2021−23.77%
2020+22.02%
2019−19.17%
2018+22.80%
2017+516.04%
2016 (partial year)+92.26%

As of October 21, 2026.

MDGL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$958.40M−$288.28M−30.1%
2024$180.13M−$465.89M−258.6%
2023$0.00−$373.63M—
2022$0.00−$295.35M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$958.40M$902.26M−$300.10M−$288.28M−30.1%
2024$180.13M$173.90M−$497.88M−$465.89M−258.6%
2023$0.00$0.00−$380.50M−$373.63M—
2022$0.00$0.00−$293.57M−$295.35M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MDGL Valuation vs Biotechnology Median

Median of 608 stocks
MetricMDGLBiotechnology medianvs median
P/S ratio8.2413.3038% below
Profit margin−25.32%−38.31%13.0 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Madrigal Pharmaceuticals, Inc. (MDGL) is capitalised at $10.58B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 915 employees.

The most recent close on file for MDGL is $457.96, dated October 21, 2026. That is −$9.58 (−2.05%) against the previous close. The 52-week range on file runs from $393.61 to $615.00. The latest close sits 16.35% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $958.40M. That is +432.05% against the prior fiscal year, when revenue was $180.13M. The same year closed with a net loss of $288.28M. The reported profit margin is −25.32%. That is 13 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are −12.85.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $958.40M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 47.58. Measured against sales, the shares trade at 8.24 times revenue. On price-to-sales that is 38.03% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Beta against the wider market is reported at −1.05. Daily returns over the trailing 10 years annualize to a volatility of 116.32%. The trailing one-year total return is +6.50%. Across 10 years the annualized return works out at +39.01%.

Growth & Income

No dividend is on file for MDGL.

Across the complete calendar years on file, 2017 returned +516.04% and 2021 returned −23.77%. Of the 9 complete calendar years on file, 6 finished higher. So far in 2026 the total return is −21.36%.

Peer Comparison

Madrigal Pharmaceuticals, Inc. (MDGL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Madrigal Pharmaceuticals, Inc. MDGL $10.58B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Madrigal Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Visit website →